MA-EVALUATE
4.6.2019 14:02:06 CEST | Business Wire | Press release
The $1.18tr forecast for the 2024 global prescription drug market reflects the role new technologies will play in addressing unmet medical needs, as strong expectations for immuno-oncology products and emerging cell and gene therapies drive growth. In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and the projected CAGR of 6.9% from 2019-2024 significantly outpaces the 2.3% CAGR seen from 2010-2018.
Growth Drivers:
- 2018 saw 62 FDA approvals for novel drugs, an increase over the 55 approvals in 2017
- Oncology therapies to reach $237bn in 2024, with a CAGR of 11.4%
- Orphan Drugs will contribute an additional $109bn in sales in 2024, compared to 2018
However, as more new technologies reach the market, drug pricing pressure may continue to intensify and dampen the overall sales outlook. R&D spending is also forecast to grow more slowly from 2019-2024 than in prior years, and decrease as a proportion of overall sales – a sign of either increasing R&D efficiency, or of companies focusing on smaller indications with lower clinical development costs.
Growth Brakes:
- $198bn in sales are at risk between 2019 and 2024, due to patent expirations
- Anti-rheumatics sales decline as Humira, Enbrel and Remicade face competition
- R&D as a proportion of prescription sales is forecast to decline from 21.6% in 2018 to 18% in 2024
“Scientific advancements and health technologies are converging to deliver new options for patients, while challenging traditional drug development and commercialisation models,” said report author Ryan Waters. “The question is, which companies are best poised to take advantage of the evolving pharmaceutical market?”
Top Performers:
- Pfizer will be the leading prescription drug company in 2024, with projected sales of $51.2bn
- Keytruda is forecast to be the top selling drug in 2024, as Humira slips in the face of biosimilars
- Johnson & Johnson overtakes Roche to be the biggest spender on pharmaceutical R&D in 2024
Download your complimentary copy of the “EvaluatePharma® World Preview 2019, Outlook to 2024” at https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024 , or visit us at Booth #2243 at the BIO International Convention, June 3-6, in Philadelphia, PA.
About Evaluate Ltd.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. Our EvaluatePharma® and EvaluatePharma Vision online subscription services provide a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com .
Follow us on Twitter: @EvaluatePharma, @Vantageanalysis
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005091/en/
Contact:
Media Contact: Evaluate and Vantage Jennifer Dinkel +1 617-936-7783 jennifer.dinkel@evaluate.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran showcases open optical networking for AI infrastructure at OIF’s ECOC 2026 interop demo17.9.2026 14:00:00 CEST | Press release
News summary: Open optical ecosystems give operators greater flexibility and vendor choice as they scale networks for the AI era Adtran’s pluggable coherent ZR+ transceivers, FSP 3000 OLS and Mosaic Network Controller key to open transport and hierarchical control in OIF demo Adtran also hosted the OIF test run in its system integration labs in Gdynia, Poland, helping to ensure the demo’s success at the show Adtran today announced its participation in OIF’s live multi-vendor interoperability demo at ECOC 2026, taking place September 21 to 23 in Málaga, Spain. Bringing together 39 member companies, the showcase highlights interoperable optical transport, pluggable coherent transceivers and network control technologies in a multi-vendor environment. Adtran is contributing 100Gbit/s, 400Gbit/s and 800Gbit/s ZR+ pluggables, its FSP 3000 open line system (OLS) operating across C- and L-bands and Mosaic Network Controller software. Ahead of the event, Adtran also hosted the OIF test run in G
IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed17.9.2026 13:00:00 CEST | Press release
New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916599752/en/ IFF has launched Omni-Bos™ PHY, a phytase enzyme developed specifically for dairy cattle, that helps producers unlock nutrients already present in feed to improve nutrient utilization and feed efficiency. “We believe the future of dairy nutrition is helping cows receive m
EdgeConneX Appoints SVP of Global Construction Delivery, Vice Presidents for Norway and Germany17.9.2026 13:00:00 CEST | Press release
New leaders to drive customer delivery and success, market development and growth, and community engagement EdgeConneX®, a global leader in Build-to-Suit and Build-to-Density digital infrastructure solutions, today announced the appointments of Garry O’Leary as SVP, Delivery, Global, Anders Hilt as Vice President of Norway, and Michael Barth as Vice President of Germany. All three hires bring a deep commitment to building strong local relationships and will play a key role in advancing the company's global projects and supporting community engagement and local support efforts. EdgeConneX continues to expand its platform globally, with gigawatts of major projects underway across multiple continents. As SVP, Delivery, Global, Garry plays a critical role in delivering the company's new capacity on time and on budget, overseeing regional construction leadership, contractor and vendor management, site safety, quality assurance, and supply chain. Prior to joining EdgeConneX, Garry was Vice P
Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right17.9.2026 12:40:00 CEST | Press release
Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life. Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260911054017/en/ Oral-B iO9 makes a superior clean easier to achieve every day. Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the
Former Colombian President Iván Duque Appointed to Advance ICC and Carbon Measures' Global Product-Level Carbon Accounting Initiative17.9.2026 12:00:00 CEST | Press release
Duque will chair the ICC & Carbon Measures Technical Expert Panel Advisory Group, bringing policy, business and practitioner perspectives into the next phase of their work. The International Chamber of Commerce (ICC) and Carbon Measures today announced that Iván Duque Márquez, former President of Colombia, has been named Chair of the newly created Technical Expert Panel Advisory Group established to complement the work of the TEP on Carbon Accounting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915635710/en/ The TEP, co-convened by ICC and Carbon Measures, brings together recognized experts from academia, financial accounting, industry and civil society to develop a globally applicable carbon emissions accounting framework. The TEP’s work comes amid growing global momentum toward harmonization of carbon accounting. The Advisory Group was created to take the TEP’s technical work to the next level, broadening engagement
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom